<DOC>
	<DOCNO>NCT02353312</DOCNO>
	<brief_summary>To study hypothesis treat patient underlie diastolic dysfunction oral KuvanÂ® ( BH4 , also know tetrahydrobiopterin ) addition current best practice improve metabolic echocardiographic diastolic function parameter .</brief_summary>
	<brief_title>Rhode Island Diastolic Dysfunction - Heart Failure</brief_title>
	<detailed_description>Congestive heart failure carry significant epidemiologic economic burden today 's healthcare system associate increased morbidity mortality affect . There approximately 5 million people United States heart failure , , nearly half heart failure preserve ejection fraction ( HFpEF ) . HFpEF , also refer diastolic heart failure , clinical syndrome characterize prolonged relaxation myocardium result symptom include dyspnea , edema , fatigue , decrease exercise tolerance , clinically indistinguishable presentation heart failure reduce ejection fraction ( HFrEF ) . The underlying mechanism diastolic dysfunction clearly elucidate , make target therapy challenge . There currently FDA approve treatment syndrome , multiple clinical trial demonstrate standard treatment systolic heart failure ineffective treat diastolic dysfunction . One propose underlie mechanism diastolic dysfunction via reduction nitric oxide ( NO ) , endothelium-derived vasodilator regulate blood pressure regional blood flow . In 2010 , Silberman et al . examined effect cardiac oxidation nitric oxide find depletion tetrahydrobiopterin ( BH4 ) , essential cofactor production nitric oxide , cause uncouple nitric oxide synthase , impaired relaxation cardiac myocytes , lead subsequent diastolic dysfunction . The author go demonstrate treatment BH4 improve diastolic dysfunction hypertensive mouse model well isolated cardiac myocytes may play role treatment HFpEF . To investigator ' knowledge , role BH4 treat diastolic dysfunction human subject study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>1 . Male female U.S . Veteran patient age eighteen , echocardiographic finding &gt; = Grade 2 diastolic dysfunction [ per American Society Echocardiography guideline ] 2 . Diagnosis hypertension , diabetes , heart failure medical record . 3 . Eligible subject must ambulatory ( dependent ambulatory assist device include cane walker ) . 1 . Any history document ejection fraction &lt; 50 % 2 . Significant COPD ( define oxygendependent COPD ) 3 . Acute coronary syndrome within past three month define EKG change biomarkers myocardial necrosis ( ie . elevate troponin ) set chest pain anginal equivalent ) 4 . Presence hypertrophic cardiomyopathy 5 . Presence infiltrative/restrictive cardiomyopathy 6 . Echocardiographic evidence moderate severe aortic mitral valve stenosis regurgitation 7 . Previously diagnose phenylketonuria 8 . End stage renal disease require hemodialysis 9 . Preexisting seizure disorder 10 . Terminal illness ( include heart failure ) expect survival one year le 11 . Females pregnant breastfeeding . All female child bear age undergo pregnancy test prior randomization . 12 . Recent hospitalization within three month . 13 . Previous Bioprosthetic and/or mechanical aortic mitral valve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diastolic</keyword>
	<keyword>Biopterin</keyword>
	<keyword>Therapeutic Use</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Quality Life</keyword>
</DOC>